Quest Partners LLC Buys 1,312 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Quest Partners LLC grew its holdings in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) by 21.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 7,458 shares of the company’s stock after acquiring an additional 1,312 shares during the quarter. Quest Partners LLC’s holdings in Nurix Therapeutics were worth $168,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of NRIX. Russell Investments Group Ltd. boosted its position in shares of Nurix Therapeutics by 75.6% during the 1st quarter. Russell Investments Group Ltd. now owns 53,542 shares of the company’s stock valued at $787,000 after acquiring an additional 23,044 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in shares of Nurix Therapeutics by 3.7% during the 1st quarter. Public Employees Retirement System of Ohio now owns 50,838 shares of the company’s stock valued at $747,000 after acquiring an additional 1,820 shares during the last quarter. Opaleye Management Inc. bought a new stake in shares of Nurix Therapeutics during the 1st quarter valued at about $3,928,000. GAMMA Investing LLC boosted its position in shares of Nurix Therapeutics by 299.8% during the 2nd quarter. GAMMA Investing LLC now owns 4,566 shares of the company’s stock valued at $95,000 after acquiring an additional 3,424 shares during the last quarter. Finally, SG Americas Securities LLC boosted its position in shares of Nurix Therapeutics by 365.0% during the 2nd quarter. SG Americas Securities LLC now owns 103,199 shares of the company’s stock valued at $2,154,000 after acquiring an additional 81,005 shares during the last quarter.

Nurix Therapeutics Stock Performance

Shares of NRIX stock opened at $21.23 on Thursday. The firm has a market cap of $1.50 billion, a P/E ratio of -7.30 and a beta of 2.20. Nurix Therapeutics, Inc. has a fifty-two week low of $5.68 and a fifty-two week high of $29.56. The business’s 50 day moving average price is $24.17 and its 200-day moving average price is $21.70.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Friday, October 11th. The company reported ($0.67) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.67). Nurix Therapeutics had a negative return on equity of 63.39% and a negative net margin of 313.65%. The firm had revenue of $12.59 million for the quarter, compared to analyst estimates of $13.85 million. As a group, equities analysts predict that Nurix Therapeutics, Inc. will post -2.81 EPS for the current year.

Insider Activity at Nurix Therapeutics

In other Nurix Therapeutics news, insider Christine Ring sold 3,290 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $25.00, for a total value of $82,250.00. Following the sale, the insider now directly owns 24,592 shares of the company’s stock, valued at approximately $614,800. The trade was a 11.80 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Houte Hans Van sold 2,368 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was sold at an average price of $24.30, for a total value of $57,542.40. Following the completion of the sale, the chief financial officer now directly owns 37,270 shares in the company, valued at $905,661. This trade represents a 5.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,451 shares of company stock worth $663,160 over the last ninety days. 7.20% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

NRIX has been the topic of a number of research reports. HC Wainwright raised their price objective on Nurix Therapeutics from $26.00 to $30.00 and gave the company a “buy” rating in a report on Monday, October 21st. Robert W. Baird initiated coverage on Nurix Therapeutics in a report on Friday, September 6th. They set an “outperform” rating and a $26.00 price objective on the stock. Oppenheimer raised their price objective on Nurix Therapeutics from $27.00 to $30.00 and gave the company an “outperform” rating in a report on Wednesday, September 4th. Stephens reissued an “overweight” rating and set a $31.00 price objective on shares of Nurix Therapeutics in a report on Monday, October 14th. Finally, Needham & Company LLC reissued a “buy” rating and set a $29.00 price objective on shares of Nurix Therapeutics in a report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $29.40.

Nurix Therapeutics Profile

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.